4.41
+0.09(+2.08%)
Currency In USD
| Previous Close | 4.32 |
| Open | 4.31 |
| Day High | 4.43 |
| Day Low | 4.25 |
| 52-Week High | 5.1 |
| 52-Week Low | 2.71 |
| Volume | 610,894 |
| Average Volume | 1.03M |
| Market Cap | 845.39M |
| PE | -15.21 |
| EPS | -0.29 |
| Moving Average 50 Days | 3.75 |
| Moving Average 200 Days | 3.43 |
| Change | 0.09 |
If you invested $1000 in Arbutus Biopharma Corporation (ABUS) 10 years ago, it would be worth $733.78 as of September 29, 2025 at a share price of $4.41. Whereas If you bought $1000 worth of Arbutus Biopharma Corporation (ABUS) shares 5 years ago, it would be worth $1,386.79 as of September 29, 2025 at a share price of $4.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
GlobeNewswire Inc.
Jun 25, 2025 11:30 AM GMT
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
GlobeNewswire Inc.
May 07, 2025 6:01 AM GMT
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibit
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
GlobeNewswire Inc.
Apr 23, 2025 6:01 AM GMT
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease